Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

ACTAVIS INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Watson Says Received Favorable Ruling Over Generic Sanctura XR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2012 | 12:19am CEST

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; [email protected]

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACTAVIS INC
04/20Japan's Takeda sweetens $62 billion Shire offer
RE
04/20LONDON MARKETS : FTSE 100 Ends At 11-week High As Pound Falls On BOE Rate-hike D..
DJ
04/20ALLERGAN : Showcases Leadership in Neurosciences with 25 Presentations at the Am..
PU
04/20Shire rejects third Takeda bid, Allergan mulling offer
AQ
04/20Shire rejects third Takeda bid, as Allergan drops out
AQ
04/20Shire Attracts Flurry Of Suitors -- WSJ
DJ
04/19Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
04/19Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
04/19Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
04/19ALLERGAN : Does Not Intend to Make an Offer for Shire plc; Strategic Review Cont..
PR
More news
Financials ($)
Sales 2018 15 225 M
EBIT 2018 7 285 M
Net income 2018 -908 M
Debt 2018 23 926 M
Yield 2018 1,84%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,17x
EV / Sales 2019 4,83x
Capitalization 54 802 M
Chart ACTAVIS INC
Duration : Period :
Actavis Inc Technical Analysis Chart | US9426831031 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 208 $
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC54 802
JOHNSON & JOHNSON-8.71%339 783
PFIZER1.13%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.17%191 890
MERCK AND COMPANY4.55%158 571